| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
Both HDAC and PI3K are considered to be promising targets for cancer therapy. A combination of an HDAC inhibitor and a PI3K inhibitor potentiates the cytotoxic effect in a synergistic manner. Therefore, development of an HDAC/PI3K dual inhibitor will provide an attractive novel drug. The depsipeptide analogs have been identified as HDAC/PI3K dual inhibitors. Moreover, using structure based optimization, FK-A11 has been identified as the most potent analog. FK-A11 showed anti-tumor effects in vivo mouse model using human prostate cancer cells.
|
